Novakand Pharma (3EE0) Stock Overview
Develops drugs for inflammatory diseases and cancer in Sweden and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
3EE0 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Novakand Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.0001 |
| 52 Week High | SEK 0.16 |
| 52 Week Low | SEK 0.0001 |
| Beta | 0.89 |
| 1 Month Change | 0% |
| 3 Month Change | -99.90% |
| 1 Year Change | -99.92% |
| 3 Year Change | -99.94% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3EE0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | -0.5% |
| 1Y | -99.9% | -32.5% | 14.2% |
Return vs Industry: 3EE0 underperformed the German Biotechs industry which returned -34.3% over the past year.
Return vs Market: 3EE0 underperformed the German Market which returned 13.5% over the past year.
Price Volatility
| 3EE0 volatility | |
|---|---|
| 3EE0 Average Weekly Movement | 9,215.7% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 12.4% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 3EE0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 3EE0's weekly volatility has increased from 4785% to 9215% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 5 | Peter Selin | novakand.com |
Novakand Pharma AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops KAN571, a ROR1 inhibitor for the treatment of mantle cell lymphoma and B-cell malignancy.
Novakand Pharma AB (publ) Fundamentals Summary
| 3EE0 fundamental statistics | |
|---|---|
| Market cap | €2.33m |
| Earnings (TTM) | -€3.64m |
| Revenue (TTM) | n/a |
Is 3EE0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3EE0 income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 39.88m |
| Earnings | -SEK 39.88m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 21, 2025
| Earnings per share (EPS) | -0.33 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 3EE0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/31 23:36 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Novakand Pharma AB (publ) is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Johan Stromqvist | ABG Sundal Collier Sponsored |
| Martin Wahlstrom | Redeye |
| Filip Lindkvist | Redeye |